Literature DB >> 8081835

Evaluation of functional analogs of CC-1065 and the duocarmycins incorporating the cross-linking 9a-chloromethyl-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-on e (C2BI) alkylation subunit.

D L Boger1, D S Johnson, M S Palanki, P A Kitos, J Chang, P Dowell.   

Abstract

The DNA alkylation properties and in vitro cytotoxic activity of a series of analogs of CC-1065 and the duocarmycins incorporating the 9a-chloromethyl-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (C2BI) alkylation subunit are detailed. The C2BI-based agents have been shown to alkylate DNA within the minor groove in a fashion analogous to CC-1065 or duocarmycin. The stereoelectronically-controlled adenine N3 addition to the least substituted cyclopropane carbon occurs with a selectivity that represents a composite of the two enantiomers of the corresponding CBI-based agents. Additional high affinity alkylation sites were detected which were not prominent alkylation sites for either enantiomer of the CBI-based agents. Such sites may represent induced high affinity alkylation sites resulting from DNA cross-linking following complementary strand alkylation at a high affinity alkylation site and each such site detected proved consistent with predicted models of an adenine-adenine cross-linking event. Further, consistent with this interpretation, the C2BI agents were shown to constitute efficient cross-linking agents with DNA cross-linking being observed at the same concentrations as DNA alkylation. In comparison to the parent CBI-based agents, the C2BI-based agents proved to be approximately 100-10,000x less effective at DNA alkylation and 100-10,000x less potent in cytotoxic assays. This is suggested to be the consequence of a significant steric deceleration of the adenine N3 alkylation reaction attributable to the additional 9a-chloromethyl substituent. Consistent with this interpretation, the noncovalent binding constant of C2BI-CDPI2 for poly[dA]-poly[dA]-poly[dT] proved nearly identical to that of CDPI3 under kinetic binding conditions, and prolonged incubation of C2BI-CDPI2 with poly[dA]-poly[dT] (72 h, 25 degrees C) provided covalent complexes with a helix stabilization comparable to that observed with (+)- or (-)-CPI-CDPI2 indicating that the size of the C2BI subunit inhibits but does not preclude productive DNA alkylation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8081835     DOI: 10.1016/s0968-0896(00)82100-8

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  5 in total

1.  Asymmetric total synthesis of (+)- and ent-(-)-yatakemycin and duocarmycin SA: evaluation of yatakemycin key partial structures and its unnatural enantiomer.

Authors:  Mark S Tichenor; John D Trzupek; David B Kastrinsky; Futoshi Shiga; Inkyu Hwang; Dale L Boger
Journal:  J Am Chem Soc       Date:  2006-12-13       Impact factor: 15.419

2.  Synthesis and characterization of a cyclobutane duocarmycin derivative incorporating the 1,2,10,11-tetrahydro-9H-cyclobuta[c]benzo[e]indol-4-one (CbBI) alkylation subunit.

Authors:  James P Lajiness; Dale L Boger
Journal:  J Am Chem Soc       Date:  2010-10-06       Impact factor: 15.419

Review 3.  CC-1065 and the duocarmycins: unraveling the keys to a new class of naturally derived DNA alkylating agents.

Authors:  D L Boger; D S Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-25       Impact factor: 11.205

4.  The Difference a Single Atom Can Make: Synthesis and Design at the Chemistry-Biology Interface.

Authors:  Dale L Boger
Journal:  J Org Chem       Date:  2017-10-13       Impact factor: 4.354

Review 5.  Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs.

Authors:  Elena Díaz-Rodríguez; Lucía Gandullo-Sánchez; Alberto Ocaña; Atanasio Pandiella
Journal:  Cancers (Basel)       Date:  2021-12-29       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.